SRPT May 2024 170.000 call
| Previous close | 1.6000 |
| Open | 0.1100 |
| Bid | 0.0000 |
| Ask | 2.1500 |
| Strike | 170.00 |
| Expiry date | 2024-05-31 |
| Day's range | 0.1100 - 0.1700 |
| Contract range | N/A |
| Volume | |
| Open interest | 211 |
Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 31, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 9 individuals hired by Sarepta in May 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(
ZacksSarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR NewswireSarepta Therapeutics Set to Join S&P MidCap 400
Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
